Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost-effective treatment of refractory angina. A phase II randomized, double-blinded, placebo-controlled study.

This study is exploring a new way to treat refractory angina, a type of severe chest pain that doesn't get better with standard medicines or treatments. People with refractory angina often find it hard to do everyday activities because of their chest pain. The new treatment being tested uses something called VEGF-D, which aims to help the heart recover or regenerate. Think of it like trying to mend or grow new connections in the heart muscle to improve blood flow and reduce pain.

The main goal of this research is to see if this new VEGF-D treatment can make a real difference in people's lives. Specifically, the doctors want to check two things: first, if people can walk further without pain after receiving the treatment (measured by a 6-minute walking test), and second, if their chest pain symptoms improve as judged by a widely used scale called the Canadian Cardiovascular Society (CCS) class. They hope these improvements will show that the new treatment is effective.

This is a 'Phase II' study, which is an important step in developing new medicines. It means the treatment has already been shown to be safe in a small group of people, and now researchers are looking more closely at its effectiveness and safety in a larger group. By comparing the new treatment to a 'dummy' treatment (placebo), they can be sure that any benefits seen are genuinely due to the VEGF-D and not just other factors.